Joe DePinto, MBA, head of cell, gene and advanced therapies at McKesson , met with MHE at the annual Asembia Specialty Pharmacy Summit in Las Vegas this week to give some insight on where we are with cell and gene therapies, as well as looking at Pfizer's discontinued hemophilia B gene therapy, Beqvez (fidanacogene elaparvovec-dzkt).
A future where healthcare may include augmented reality, robots and drones may be more fact than fiction, says George Van Antwerp, SVP of product innovation and strategic planning at Prime Therapeutics.
As healthcare AI evolves, there will be a greater emphasis on streamlining administrative tasks, drug production and service delivery, according to George Van Antwerp, SVP of product innovation and strategic planning at Prime Therapeutics.
Shawn Griffin, M.D., president and CEO of URAC, shared his insights into best practices for promoting health equity during the annual Asembia Specialty Pharmacy Summit in Las Vegas today.
At this year’s Asembia conference in Las Vegas, Shawn Griffin, M.D., president and CEO of URAC, spoke about the need for strong leadership and community-based data in specialty pharmacies to identify and address health disparities, which will then improve care for all patients.
Managed Healthcare Executive asked several experts in healthcare and managed care to share the trends they think the industry is overlooking. From rising costs and data challenges to shifts in how care is delivered, these are the issues that could have a major impact — and deserve a closer look.
Patients and providers found common ground on the importance of correct billing estimates but did not see eye to eye in terms of digital scheduling tool use, according to a new survey by Experian Health.
There is a lack of agreement on the clinical, psychological and social relevance of menopause between the transgender and gender diverse communities and medical professionals, according to the results of a study published this month in Menopause.
Researchers of a new JAMA study said that without further participation in accountable care organizations, including the ACO REACH model, the program is unlikely to meet its goal of reducing health disparities.
CVS Health released a statement shortly after HB1150 was signed in Arkansas, prohibiting pharmacy benefit managers from owning pharmacies.
In a recent conversation with Managed Healthcare Executive, Geoffrey Rutledge, M.D., of HealthTap, warned that the narrative around GLP-1 drugs is often oversimplified—and potentially harmful.
On lobbying, hospitals, PBM reform and 340B
On lobbying, the political power of hospitals, PBM reform and 340B
Women who undergo menopause before the age of 40 are more likely to experience cognitive decline, which may lead to dementia, according to new research.
Here’s what you missed this week on Managed Healthcare Executive.
Maureen Corcoran, director of the Ohio Department of Medicaid, believes the work requirement policy can be both a financial and moral effort to improve the lives of Medicaid consumers.
Medicaid is the main healthcare coverage for people living with HIV in the United States, according to data compiled by KFF.
With policymakers considering work requirements for Medicaid eligibility, Jennifer Haley, principal research associate in the Health Policy Division at the Urban Institute, said it’s more important than ever to understand how those changes could unintentionally cause harm, particularly when data systems fall short and public awareness is limited.
The difference between specialty drugs and traditional drugs and how each have vied for market competition, according to Jeff Casberg, MS, RPh, senior vice president of clinical pharmacy services at IPD Analytics.
The insurer’s healthcare expenses, especially physician and outpatient services, within the Medicare Advantage businesses were above what company leaders had expected.
In this first part of a two-part video series, Jennifer Haley, principal research associate of the Health Policy Division at the Urban Institute, spoke with MHE about the impact the proposed Medicaid work requirements could have on millions and research that supports this belief.
A Q&A between Shawn Kwatra, M.D., professor and chair of dermatology at the University of Maryland School of Medicine, and Managed Healthcare Executive about new discoveries in chronic itch, how treatment options are improving and the challenges patients face in getting access to the right therapies.
The analysis from the Urban Institute breaks down projected coverage losses across the 40 Medicaid expansion states, where researchers based their estimates on previous work requirement rollouts in Arkansas and New Hampshire.
In a Q&A with Jeff Casberg, MS, RPh, senior vice president of clinical pharmacy services at IPD Analytics, Casberg explains the evolution of specialty drugs, the future of GLP-1 competition and what to expect from the traditional drug pipeline.
Here’s what you missed this week on Managed Healthcare Executive.
Qfitlia (fitusiran) is the first therapy for both hemophilia A or B, with or without inhibitors, available in the United States.
The CEOs of CVS Health and UnitedHealth Group praised pharmacy benefit managers and promised transparency during investor calls. A critic of the “big 3” dismissed the statements as posturing.
Several drugs in development would block neonatal fragment crystallizable receptor (FcRn) as a way of reducing the autoantibodies that cause myasthenia gravis.
Current observations and foresight into the world of biosimilars, GLP-1s, PBM and payer trends, according to Jeff Casberg, MS, RPh, senior vice president of clinical pharmacy services at IPD Analytics, and Doug Long, MBA, vice president of industry relations at IQVIA.
In United States veterans, antiretroviral resistance was associated with higher healthcare resource utilization, despite lower pharmacy-related costs, according to an abstract submitted to the Academy of Managed Care Pharmacy (AMCP) held last week in Houston.
